Advertisement

Psychopharmacology

, Volume 234, Issue 15, pp 2233–2244 | Cite as

A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use

  • Keming GaoEmail author
  • Stephen J. Ganocy
  • Carla Conroy
  • Brittany Brownrigg
  • Mary Beth Serrano
  • Joseph R. Calabrese
Original Investigation

Abstract

Objective

This study aims to compare treatment response in bipolar I or II depression and generalized anxiety disorder (GAD) with and without recent alcohol and/or cannabis use disorder (ALC/CAN) to quetiapine-XR (extended release) or placebo.

Methods

A randomized, double-blind, 8-week study of quetiapine-XR versus placebo in patients with bipolar I or II depression and GAD with or without a recent ALC/CAN was used to compare changes in Hamilton Depression Rating Scale-17, Hamilton Anxiety Rating Scale, the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16), Clinical Global Impression for Bipolar Disorder-Severity (CGI-BP-S), and Timeline Follow Back within and between groups.

Results

In the quetiapine-XR group, patients with a recent ALC/CAN (n = 22) had significant decreases in QIDS-SR-16 (−9.6 ± 1.6 vs. −3.7 ± 1.7) and CGI-BP-S (−1.6 ± 0.4 vs. −0.8 ± 0.03) than those without a recent ALC/CAN (n = 24). In the placebo group, both patients with a recent ALC/CAN (n = 23) and those without (n = 21) had similar reductions in these measures. The reduction of QIDS-SR-16 scores in patients with a recent ALC/CAN was also significantly different from that of their counterparts in the placebo group. Patients who received quetiapine-XR had larger decreases in the number of drinking days/week (p = 0.17) and number of cannabis joints/week (p = 0.09) compared to those who received placebo.

Conclusion

Quetiapine-XR was superior to placebo in reducing QIDS-SR-16 total score in patients with a recent ALC/CAN. Patients taking quetiapine-XR used less alcohol and cannabis than patients on placebo, suggesting that quetiapine-XR may be of use in patients with bipolar disorder accompanied by GAD and other comorbidities.

Keywords

Bipolar disorder Quetiapine Generalized anxiety disorder Substance use disorder Randomized Placebo-controlled trial 

Notes

Compliance with ethical standards

Disclosure of conflict of interest

J.R.C. has received federal funding from the Department of Defense, Health Resources Services Administration and National Institute of Mental Health as well as grant support from Abbott Laboratories; AstraZeneca; Bristol-Myers Squibb Company; Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.); Dainippon Sumitomo Pharma Co., Ltd.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; Intra-Cellular Therapies, Inc.; Pfizer, Inc.; H. Lundbeck A/S; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited. J.R.C. has served as a consultant/advisory board member/speaker for Abbott Laboratories; Allergan; AstraZeneca; Bristol-Myers Squibb Company; Cephalon, Inc. (now Teva Pharmaceutical Industries Ltd.); Dainippon Sumitomo Pharma Co., Ltd.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; H. Lundbeck A/S; Merck & Co., Inc.; Otsuka Pharmaceutical Co., Ltd.; Pfizer, Inc.; Repligen Corporation; Servier; Sunovion Pharmaceuticals Inc.; Solvay Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

K.G. has been on a speakers bureau and an advisory board of Sunovion, and received grant support from AstraZeneca, Brain and Behavior Research Foundation, and Cleveland Foundation.

S.J.G. has received grant support from AstraZeneca and Eli Lilly and Company.

Other authors have no conflicts of interest to disclose.

Funding sources

This study was initiated with a Young Investigator Award from NARSAD (currently Brain and Behavior Research Foundation) and further supported by AstraZeneca Pharmaceutical Company via an Investigator Initiated Study.

References

  1. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H (2010) Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13:305–320CrossRefPubMedGoogle Scholar
  2. Bauer MS, Altshuler L, Evans DR, Beresford T, Williford WO, Hauger R, VA Cooperative Study #430 Team (2005) Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder. J Affect Disord 85:301–315CrossRefPubMedGoogle Scholar
  3. Brown ES, Gorman AR, Hynan LS (2007) A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 27:498–502CrossRefPubMedGoogle Scholar
  4. Brown ES, Garza M, Carmody TJ (2008) A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry 69:701–705CrossRefPubMedGoogle Scholar
  5. Brown ES, Carmody TJ, Schmitz JM, Caetano R, Adinoff B, Swann AC, John Rush A (2009) A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res 33:1863–1869CrossRefPubMedPubMedCentralGoogle Scholar
  6. Brown ES, Sunderajan P, Hu LT, Sowell SM, Carmody TJ (2012) A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology 37:2347–2354CrossRefPubMedPubMedCentralGoogle Scholar
  7. Brown ES, Davila D, Nakamura A, Carmody TJ, Rush AJ, Lo A, Holmes T, Adinoff B, Caetano R, Swann AC, Sunderajan P, Bret ME (2014) A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol Clin Exp Res 38:2113–2118CrossRefPubMedPubMedCentralGoogle Scholar
  8. Brown ES, Todd JP, Hu LT, Schmitz JM, Carmody TJ, Nakamura A, Sunderajan P, Rush AJ, Adinoff B, Bret ME, Holmes T, Lo A (2015) A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry 172:1014–1021CrossRefPubMedGoogle Scholar
  9. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J (2005) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351–1360CrossRefPubMedGoogle Scholar
  10. Dawson DA, Grant BF, Stinson FS, Chou PS (2005) Psychopathology associated with drinking and alcohol use disorders in the college and general adult populations. Drug Alcohol Depend 77:139–150CrossRefPubMedGoogle Scholar
  11. Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29:321–326PubMedGoogle Scholar
  12. First MB, Spitzer RL, Gibbon M, Williams JB (1997) Structured clinical interview for the diagnostic and statistical manual of mental disorders, fourth Edition, patient version. American Psychiatric Press, WashingtonGoogle Scholar
  13. Frank E, Cyranowski JM, Rucci P, Shear MK, Fagiolini A, Thase ME, Cassano GB, Grochocinski VJ, Kostelnik B, Kupfer DJ (2002) Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar disorder. Arch Gen Psychiatry 59:905–911CrossRefPubMedGoogle Scholar
  14. Gao K, Verduin ML, Kemp DE, Tolliver BK, Ganocy SJ, Elhaj O, Bilali S, Brady KT, Findling RL, Calabrese JR (2008a) Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trials. J Clin Psychiatry 69:1057–1063CrossRefPubMedPubMedCentralGoogle Scholar
  15. Gao K, Tolliver B, Kemp DE, Verduin ML, Ganocy SJ, Bilali S, Brady K, Shim SS, Findling RL, Calabrese JR (2008b) Differential interactions between comorbid anxiety and substance use disorder in rapid cycling bipolar I or II disorder. J Affect Disord 110:167–173CrossRefPubMedPubMedCentralGoogle Scholar
  16. Gao K, Sheehan DV, Calabrese JR (2009) Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 9:1147–1158CrossRefPubMedPubMedCentralGoogle Scholar
  17. Gao K, Kemp DE, Conroy C, Ganocy SJ, Findling RL, Calabrese JR (2010) Comorbid anxiety and substance use disorders associated with a lower use of mood stabilisers in patients with rapid cycling bipolar disorder: a descriptive analysis of the cross-sectional data of 566 patients. Int J Clin Pract 64:336–344CrossRefPubMedPubMedCentralGoogle Scholar
  18. Gao K, Wang Z, Chen J, Kemp DE, Chan PK, Conroy CM, Serrano MB, Ganocy SJ, Calabrese JR (2013) Should an assessment of Axis I comorbidity be included in the initial diagnostic assessment of mood disorders? Role of QIDS-16-SR total score in predicting number of Axis I comorbidity. J Affect Disord 148:256–264CrossRefPubMedGoogle Scholar
  19. Gao K, Wu R, Kemp DE, Chen J, Karberg E, Conroy C, Chan P, Ren M, Serrano MB, Ganocy SJ, Calabrese JR (2014) Efficacy and safety of quetiapine-XR monotherapy or adjunctive therapy to mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial. J Clin Psychiatry 75:1062–1068CrossRefPubMedGoogle Scholar
  20. Gao K, Wu R, Wang Z, Ren M, Kemp DE, Chan PK, Conroy CM, Serrano MB, Ganocy SJ, Calabrese JR (2015) Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder. J Psychiatr Res 60:117–124CrossRefPubMedGoogle Scholar
  21. Geller B, Cooper TB, Sun K, Zimerman B, Frazier J, Williams M, Heath J (1998) Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolesc Psychiatry 37:171–178CrossRefPubMedGoogle Scholar
  22. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55CrossRefPubMedGoogle Scholar
  23. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62CrossRefPubMedPubMedCentralGoogle Scholar
  24. Kemp DE, Gao K, Ganocy SJ, Elhaj O, Bilali SR, Conroy C, Findling RL, Calabrese JR (2009) A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. J Clin Psychiatry 70:113–121CrossRefPubMedGoogle Scholar
  25. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H (2011) A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol 31:418–428CrossRefPubMedGoogle Scholar
  26. Kushner MG, Abrams K, Thuras P, Thuras P, Hanson KL (2000) Individual differences predictive of drinking to manage anxiety among non-problem drinkers with panic disorder. Alcohol Clin Exp Res 24:448–458CrossRefPubMedGoogle Scholar
  27. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH, EMBOLDEN II (Trial D1447C00134) Investigators (2010) A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 71:163–174CrossRefPubMedGoogle Scholar
  28. Merideth C, Cutler AJ, She F, Eriksson H (2012) Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study. Int Clin Psychopharmacol 27:40–54CrossRefPubMedGoogle Scholar
  29. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 64:543–552CrossRefPubMedPubMedCentralGoogle Scholar
  30. Ostacher MJ, Perlis RH, Nierenberg AA, Calabrese J, Stange JP, Salloum I, Weiss RD, Sachs GS, STEP-BD Investigators (2010) Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry 167:289–297CrossRefPubMedGoogle Scholar
  31. Perlis RH, Miyahara S, Marangell LB, Wisniewski SR, Ostacher M, DelBello MP, Bowden CL, Sachs GS, Nierenberg AA, STEP-BD Investigators (2004) Long-tern implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BP). Biol Psychiatry 55:875–881CrossRefPubMedGoogle Scholar
  32. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME (2006) Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry 163:217–224CrossRefPubMedGoogle Scholar
  33. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse: results from the epidemiologic catchment area (ECA) study. J Am Med Assoc 264:2511–2518CrossRefGoogle Scholar
  34. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003) The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573–583CrossRefPubMedGoogle Scholar
  35. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, Shores-Wilson K, Biggs MM, Woo A, Nierenberg AA, Fava M (2006) An evaluation of the quick inventory of depressive symptomatology and the Hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry 59:493–501CrossRefPubMedGoogle Scholar
  36. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME (2005) Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 62:37–45CrossRefPubMedGoogle Scholar
  37. Schürhoff F, Bellivier F, Jouvent R, Mouren-Siméoni MC, Bouvard M, Allilaire JF, Leboyer M (2000) Early and later onset bipolar disorders: two different forms of manic-depressive illness. J Affect Disord 58:215–221CrossRefPubMedGoogle Scholar
  38. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The MINI-international neuropsychiatric interview (MINI): the development and validation of structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33PubMedGoogle Scholar
  39. Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE Jr, Janavs J, Rogers J, Gonzalez R, Shivakumar G, Suppes T (2009) Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord 115:376–385CrossRefPubMedGoogle Scholar
  40. Sheehan DV, Harnett-Sheehan K, Hidalgo RB, Janavs J, McElroy SL, Amado D, Suppes T (2013) Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord 145:83–94CrossRefPubMedGoogle Scholar
  41. Simmons LA, Havens JR (2007) Comorbid substance and mental disorders among rural Americans: results from the National Comorbidity Survey. J Affect Disord 99:265–271CrossRefPubMedGoogle Scholar
  42. Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, Sachs GS, Nierenberg AA, Thase ME, Pollack MH (2004a) Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 patients in the systematic treatment enhancement program for bipolar disorder (STEP-BP). Am J Psychiatry 161:222–2229Google Scholar
  43. Simon NM, Otto MW, Weiss RD, Bauer MS, Miyahara S, Wisniewski SR, Thase ME, Kogan J, Frank E, Nierenberg AA, Calabrese JR, Sachs GS, Pollack MH, STEP-BD Investigators (2004b) Pharmacotherapy for bipolar disorder and comorbid conditions baseline data from SPEP-BD. J Clin Psychopharmacol 24:512–520CrossRefPubMedGoogle Scholar
  44. Sobell LC, Sobell MB (1992) Timeline Followback: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen JP (eds) Measuring alcohol consumption: psychosocial and biological methods. Humana Press, Totowa, New Jersey, pp 41–72Google Scholar
  45. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W (1997) Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 73:159–171CrossRefPubMedGoogle Scholar
  46. Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S (2010) A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res 34:1822–1831CrossRefPubMedGoogle Scholar
  47. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D (2010) Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 121:106–115CrossRefPubMedGoogle Scholar
  48. Suppes T, McElroy SL, Sheehan DV, Hidalgo RB, Cosgrove VE, Gwizdowski IS, Feldman NS (2014) A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder. J Clin Psychiatry 75:77–84CrossRefPubMedGoogle Scholar
  49. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, BOLDER II Study Group (2006) Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600–609CrossRefPubMedGoogle Scholar
  50. Tolliver BK, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT (2012) A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord 14:54–63CrossRefPubMedGoogle Scholar
  51. Tondo L, Burrai C, Scamonatti L, Weissenburger J, Rush J (1988) Comparison between clinician-rated and self-reported depressive symptoms in Italian psychiatric patients. Neuropsychobiology 19:1–5CrossRefPubMedGoogle Scholar
  52. Wang Z, Gao K, Kemp DE, Chan PK, Serrano MB, Conroy C, Fang Y, Ganocy SJ, Findling RL, Calabrese JR (2010) Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. Psychopharmacol Bull 43:5–21PubMedPubMedCentralGoogle Scholar
  53. Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, Doreau HR, Hennen JA (2007) A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry 164:100–107CrossRefPubMedGoogle Scholar
  54. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435CrossRefPubMedGoogle Scholar
  55. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, Paulsson B, Brecher M, EMBOLDEN I (Trial 001) Investigators (2010) A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 71:150–162CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Keming Gao
    • 1
    Email author
  • Stephen J. Ganocy
    • 1
  • Carla Conroy
    • 1
  • Brittany Brownrigg
    • 1
  • Mary Beth Serrano
    • 1
  • Joseph R. Calabrese
    • 1
  1. 1.Mood and Anxiety Clinic in the Mood Disorders Program, University Hospital Cleveland Medical CenterCase Western Reserve University School of MedicineClevelandUSA

Personalised recommendations